Diabetes

Aligning community pharmacy interventions with top-down findings, payers’ population health priorities, and identified unmet needs can help develop a sustainable pathway.

The oral medication activates an “anti-hunger” molecule which may prevent people from overeating.

According to the results, approximately 82% of adults said they have heard at least a little about GLP-1 medications and 32% said they have heard a lot.

In diabetic rats, investigators found a decrease in urine biomarkers and expression of proteins that play a part in renin-angiotensin system (RAS).

Novo Nordisk and Eli Lilly have spoken out against the use of their GLP-1 medications for cosmetic weight loss, emphasizing the proper use of their medications.

Conversations and counseling points should be tailored to patients’ individual needs and treatment goals

Optical glucose sensing techniques have been reported, but they require complex optical instrumentations found in laboratories, so feasibility for patient use has been challenging.

Investigators found that the individuals’ peak cognitive performance coincided with glucose levels that were slightly above the normal range.

James Shehan shares insights on the promising trends shaping the weight loss medication and how changing views of obesity could pave the way for uptake GLP-1s.

Pharmacists can help to interpret HbA1c and glucose results when patients come to pick up medications and contact prescribers and/or make recommendations based off patient results.

James Shehan discusses the growth of the GLP-1 receptor agonist market for medicated-assisted weight loss.

Tirzepatide is currently approved for management of type 2 diabetes, improving glucose control, facilitating weight loss, and improving cardiovascular disease outcomes.

Evidence suggests foods that activate sirtuin proteins may be beneficial for metabolic syndromes

A pharmacist discusses the impact of comprehensive weight management with a shared decision making approach.

In addition to improved efficacy, newer generations of anti-obesity medications have significantly improved safety concerns.

Expert Jennifer Clements discussed the evolving landscape of weight management medications, clinical considerations, and obstacles to use.

The oral medication activates an “anti-hunger” molecule which may prevent people from overeating.

Raj Gupta, DC, discusses holistic approaches to managing type 2 diabetes without medication by addressing root causes like diet, toxins, and stress.

A notable revision now includes a dual GIP and GLP-1 receptor agonist (tirzepatide) as an additional option for glycemic management, preferred over insulin.

This guide discusses the integration of continuous glucose monitoring (CGM) technology into clinical practice, emphasizing the role of pharmacists in selecting and optimizing CGM devices for patients.

GBS can cause transcriptional adaptations, which may increase risk of poor neonate outcomes.

CGM enhances diabetes management in pregnancy, improving outcomes.

Teplizumab is indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients 8 years of age and older with stage 2 T1D.

Promising data have emerged suggesting a significant weight loss benefit for patients using GLP-1 agonists and GLP-1/GIP dual agonists.

Continuous glucose monitoring (CGM) is a valuable tool in managing diabetes, offering real-time data on glucose levels throughout the day.

Diabetes is a known risk factor for cognitive decline and small vessel disease.

Vitamin D preserved insulin-producing cells and cell function, which can reduce complications in young patients.

The continuous glucose monitoring system will be available for purchase online and without a prescription starting in summer 2024.

In the study, investigators found superior kidney outcomes with injectable semaglutide (Ozempic) for individuals with type 2 diabetes and chronic kidney disease.

In some instances, metabolites can predict risk in patients who still have normal glucose biomarkers.